UK markets closed

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.3600-0.2300 (-8.88%)
At close: 04:00PM EDT
2.3600 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.5900
Open2.5300
Bid2.3400 x 400
Ask2.3800 x 100
Day's range2.3350 - 2.5600
52-week range1.3200 - 3.4100
Volume499,491
Avg. volume817,895
Market cap601.656M
Beta (5Y monthly)-0.40
PE ratio (TTM)N/A
EPS (TTM)-0.9000
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.33
  • GlobeNewswire

    Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 at 4:00 pm ET. A live webcast of the presentation can be accessed through the Investors section of the Company's w

  • GlobeNewswire

    Lyell Immunopharma to Participate in BofA Securities Health Care Conference

    SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the BofA Securities 2024 Health Care Conference on Tuesday, May 14 at 8:40 am PT. A live webcast of the presentation can be accessed through the Investors section of the Company's website at ww

  • Simply Wall St.

    Lyell Immunopharma First Quarter 2024 Earnings: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)

    Lyell Immunopharma ( NASDAQ:LYEL ) First Quarter 2024 Results Key Financial Results Net loss: US$60.7m (loss narrowed...